Unknown News
Unknown Market News
9d
Quest Diagnostics to Offer FDA‑Cleared Roche pTau217 Alzheimer’s Test, Expanding DGX’s Advanced Diagnostics Portfolio
- Quest Diagnostics (DGX) will begin offering Roche’s FDA‑cleared pTau217 blood test for Alzheimer’s pathology, augmenting its AD‑Detect® offerings.
23d
Quest Diagnostics Declares $0.86 Quarterly Dividend Despite Quiet August
Quest Diagnostics (NYSE: DGX) has declared a $0.86 per share quarterly dividend amid minimal fresh developments in the past week.
12 Aug at 17:40
Quest Diagnostics Highlights Growing Community Health Initiatives Amid Financial Landscape
Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, has recently been involved in several significant activities that may influence its stock performance.
28 Jul at 11:23
Quest Diagnostics' Q2 2026 Earnings Surpass Expectations; Full-Year Guidance Raised
Quest Diagnostics reports strong Q2 2026 earnings, raises full-year guidance.
26 Jul at 18:09
Quest Diagnostics Reports Strong Q2 2026 Results, Raises Full-Year Guidance
Quest Diagnostics posts robust Q2 2026 earnings, boosts annual outlook.
